Radnet Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Radnet Inc (RDNT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Radnet Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,269M vs 109,067M combined for its competitors (2.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+9.8% annualized vs trailing 12 months), vs accelerating (+2.6%) for its tracked peer group.
- Growth: Radnet Inc generated 25.0% revenue growth year over year in Q2 2026, vs 9.5% for its competitors combined.
- Profitability: Its 3.3% net margin compares with 8.4% for the peer group.
- Scale: Radnet Inc ranks #13 of 46 companies by market capitalization in the Medical Laboratories industry, holding 1.7% of industry market cap.
- Peer revenue share: Radnet Inc accounted for 2.2% of combined revenue among its tracked peer group, up from 1.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.29M compares with $0.24M for the peer group (1.2x).
- Structure: Radnet Inc operates in the following segments: Imaging Centers, Digital Health; and reports the following subsidiaries: Icad Inc (competes with Hologic Inc, Medical Imaging Corp., Varian Medical Systems Inc ).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RDNT Sales vs. its Competitors, Q2 2026
Radnet Inc reported revenue growth of 24.99 % year on year in Q2 2026, above its competitors' combined revenue growth of 9.50 %.
With a net margin of 3.25 %, Radnet Inc reported lower profitability than its competitors (8.37 %).
Radnet Inc generated 2.18 % of the combined sales of its peer group, up from 1.91 % a year earlier.
API endpoints for this dataset
Radnet Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Radnet Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Radnet Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Radnet Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Radnet Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 9.0% year over year, combined, vs 25.0% for Radnet Inc. Radnet Inc's share of combined industry revenue moved from 0.91% to 1.04%, a gain of 0.13 percentage points.
Radnet Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Radnet Inc | Yes | Yes | Yes | No |
| Competitors combined (6) | ||||
| High-Confidence Competitors (2) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RDNT Stock Performance relative to its Competitors
RDNT Stock Performance relative to High-Confidence Competitors
RDNT Stock Performance relative to Similar-Size Competitors
RDNT Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Labcorp Holdings Inc | 282.9% | Outperformed |
| 2 | Quest Diagnostics Inc | 282.9% | Outperformed |
| 3 | Hca Healthcare Inc | 282.9% | Outperformed |
| 4 | Astrana Health Inc | 282.9% | Outperformed |
| 5 | Ispecimen inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Radnet Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Radnet Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Radnet Inc |
6,170.94 | 2,268.93 |
 Hca Healthcare Inc |
109,668.17 | 78,701.00 |
 Labcorp Holdings Inc |
30,341.33 | 14,594.50 |
 Quest Diagnostics Inc |
29,083.04 | 11,841.00 |
 Astrana Health Inc |
1,681.00 | 3,844.19 |
 Ispecimen inc |
1.10 | 0.47 |
| SUBTOTAL | 176,945.69 | 111,336.42 |
Sign in to see all competitors of Radnet Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Radnet Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Radnet Inc's Competitors Named by the Company
Competitive relationships identified from Radnet Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Hologic, Inc. | Company report | 85% |
| Astrana Health Inc | Company report | 85% |
| ScreenPoint Medical | Company report | 85% |
| Densitas Inc. | Company report | 85% |
| Therapixel | Company report | 85% |
| Volpara Solutions Limited | Company report | 85% |
| Medical Imaging Corp. | Company report | 85% |
| Akumin Inc | Company report | 85% |
| Accuray Incorporated | Company report | 85% |
| American Oncology Network Inc | Company report | 85% |
| Viewray Inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Fonar Corporation | Company report | 85% |
| Hyperfine Inc | Company report | 85% |
| Edap Tms Sa | Company report | 85% |
| Quest Diagnostics Inc | Company report | 85% |
| Hca Healthcare Inc | Company report | 85% |
| Labcorp Holdings Inc | Company report | 85% |
| Varian Medical Systems Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Radnet Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Radnet Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Radnet Inc | Imaging Centers 96.64 % |
| Hca Healthcare Inc | American Group 34.50 % |
| Labcorp Holdings Inc | Diagnostics 77.40 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 98.00 % |
| Astrana Health Inc | Care Partners 94.64 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Radnet Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Radnet Inc | 6,171 | 288,228 | 2,448 |
| Hca Healthcare Inc | 109,668 | 245,941 | 22,806 |
| Labcorp Holdings Inc | 30,341 | 208,493 | 14,354 |
| Quest Diagnostics Inc | 29,083 | 207,737 | 20,456 |
| Astrana Health Inc | 1,681 | 1,281,397 | 13,074 |
| Ispecimen inc | 1 | 66,615 | -1,631,418 |
| PEERS TOTAL | 170,775 | 242,364 | 21,073 |
Radnet Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 41 companies in Radnet Inc's industry classification, broader than the peer set above. Market cap in millions of $.Radnet Inc ranks #13 of 41 companies by market capitalization in its industry, holding 1.70 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 800, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Iqvia Holdings Inc | 46,650 | 12.89 % |
| 2 | Natera Inc | 45,905 | 12.68 % |
| 3 | Ge Healthcare Technologies Inc | 38,150 | 10.54 % |
| 4 | Labcorp Holdings Inc | 30,490 | 8.42 % |
| 5 | Quest Diagnostics Inc | 1,234 | 5.2% |
| 6 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 7 | Incyte Corporation | 1,234 | 5.2% |
| 8 | Guardant Health Inc | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 13 | Radnet Inc | 6,171 | 1.70 % |
Market cap and industry share for the rest of Radnet Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Radnet Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 8 | Guardant Health Inc | 21,098 | 61.65 % |
| 9 | Medpace Holdings Inc | 19,215 | 11.40 % |
| 10 | Charles River Laboratories International inc | 16,968 | 104.51 % |
| 11 | Icon Plc | 16,050 | 29.04 % |
| 12 | Billiontoone Inc | 1,234 | 12.3% |
| 13 | Radnet Inc | 6,171 | -4.97 % |
| 14 | Grail Inc | 1,234 | 12.3% |
| 15 | Caredx Inc | 1,234 | 12.3% |
| 16 | Celcuity Inc | 1,234 | 12.3% |
| 17 | Viridian Therapeutics Inc | 1,234 | 12.3% |
| 18 | Veracyte Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Radnet Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Radnet Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 33.04 % (avg) | -33.0 pp |
| Operating Margin | 3.12 % | industry median | +3.8 pp |
| EBITDA Margin | 7.71 % | -4.66 % (avg) | +12.4 pp |
| Capital Intensity (Capex / Revenue) | 28.86 % | 7.45 % (avg) | +21.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Radnet Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.0x | - |
| EV / EBITDA | 28.0x | 20.9x | +7.0x |
| P/B | 3.3x | 4.3x | -1.0x |
| Return on Equity | 1.42 % | industry aggregate | -9.89 % |
| Return on Invested Capital | 1.26 % | -7.64 % (avg) | 8.90 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Radnet Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 5.74 % | 18.36 % | -4.86 % | 20.59 % | 8.00 % | 13.05 % | 13.18 % | 11.51 % |
| Operating Margin | 3.17 % | 6.05 % | 3.25 % | 6.23 % | 3.24 % | 6.11 % | 5.72 % | 3.04 % |
| Return on Invested Capital | 3.29 % | 4.40 % | 2.12 % | 4.06 % | 1.78 % | 2.66 % | 2.23 % | 1.19 % |
| P/E | 19.2x | 68.0x | - | 62.5x | 107.9x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Radnet Inc's Strategic Group Map
Radnet Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Radnet Inc's trailing-12-month revenue growth of 18.9% and operating margin of 3.1% compares with an average of 16.0% growth and 6.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Radnet Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Radnet Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Radnet Inc falls in the Dog quadrant: relative market share of 0.13x vs its largest competitor, in an industry growing revenue 5.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Radnet Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 800 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 28.86 % vs industry average 7.45 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Radnet Inc's dedicated Suppliers and Customers pages, not here.
Radnet Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Radnet Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Radnet Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+9.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 9.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.13x).
Opportunities
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Radnet Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Radnet Inc | 1.10 | 1.61 | 0.86 |
| Hca Healthcare Inc | 0.05 | 0.90 | - |
| Labcorp Holdings Inc | 0.18 | 1.57 | 0.68 |
| Quest Diagnostics Inc | 0.28 | 1.35 | 0.74 |
| Astrana Health Inc | 0.65 | 1.34 | 1.25 |
| Ispecimen inc | 0.49 | 0.81 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Radnet Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Radnet Inc | Q2 2026 | +25.0 % | -12.1 % |
| Hca Healthcare Inc | Q3 2026 | +3.6 % | -17.0 % |
| Labcorp Holdings Inc | Q3 2026 | +6.9 % | +0.5 % |
| Quest Diagnostics Inc | Q3 2026 | +10.0 % | +20.5 % |
| Astrana Health Inc | Q2 2026 | +48.5 % | +80.6 % |
| Ispecimen inc | Q2 2026 | -78.7 % | - |
| PEERS TOTAL | +6.2 % | -11.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Radnet Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Radnet Inc | Q2 2026 | - | -16.4 % |
| Hca Healthcare Inc | Q3 2026 | - | +5.4 % |
| Labcorp Holdings Inc | Q3 2026 | +6.4 % | +56.1 % |
| Quest Diagnostics Inc | Q3 2026 | +10.1 % | +15.3 % |
| Astrana Health Inc | Q2 2026 | +53.3 % | +173.1 % |
| Ispecimen inc | Q2 2026 | -81.2 % | - |
Radnet Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Radnet Inc | 0.50% | 0.45% | 1.42% |
| Hca Healthcare Inc | 11.73% | 15.54% | - |
| Labcorp Holdings Inc | 5.36% | 6.07% | 11.55% |
| Quest Diagnostics Inc | 6.96% | 8.01% | 15.22% |
| Astrana Health Inc | 1.72% | 2.13% | 4.84% |
| Ispecimen inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Radnet Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Radnet Inc | - | 2.72 |
| Hca Healthcare Inc | 17.60 | 1.39 |
| Labcorp Holdings Inc | 30.53 | 2.08 |
| Quest Diagnostics Inc | 26.15 | 2.46 |
| Astrana Health Inc | 39.73 | 0.44 |
| Ispecimen inc | - | 2.36 |
| PEERS AVERAGE | 18.62 | 1.59 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.